| Cvs Pharmacy # 01855 | |
| 66 South Main St, Sharon, Massachusetts 02067 | |
| (781) 784-6714 |
| Name | Cvs Pharmacy # 01855 |
|---|---|
| Organization Name | Cvs Pharmacy Inc |
| Location | 66 South Main St, Sharon, Massachusetts 02067 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Phone | (781) 784-6714 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
A selection of health policy stories from Texas, Ohio, Colorado, North Carolina, Massachusetts, Alabama, Connecticut and Kansas.
July 28th is marked as world hepatitis day. The world is united in elimination of viral hepatitis by 2030. The World Health Organization (WHO) has published new data from 28 countries today and shown that nearly 70% of the world hepatitis burden is borne by these countries.
The National Research Foundation (NRF) and the Ministry of Education (MOE) announced today the funding support for a Research Centre of Excellence (RCE) called the Singapore Centre on Environmental Life Sciences Engineering (SCELSE) to be set up at the Nanyang Technological University (NTU).
Hematopoietic stem cells, that form mature blood cells, require a very precise amount of protein to function - and defective regulation of protein production is common in certain types of aggressive human blood cancers.
Researchers presented data today on ARQ 092, an AKT inhibitor in Phase 1 clinical development by ArQule, Inc. at the AACR Annual Meeting held in Washington, D.C., April 6-10, showing that this novel, oral agent inhibits the AKT pathway and has a manageable safety profile in an ongoing Phase 1 clinical trial.
› Verified 5 days ago
| NPI Number | 1568561934 |
| Organization Name | CVS PHARMACY INC |
| Doing Business As | CVS PHARMACY # 01855 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Address | 66 S Main St, Sharon, MA 02067 |
| Phone Number | 781-784-6714 |
News Archive
A selection of health policy stories from Texas, Ohio, Colorado, North Carolina, Massachusetts, Alabama, Connecticut and Kansas.
July 28th is marked as world hepatitis day. The world is united in elimination of viral hepatitis by 2030. The World Health Organization (WHO) has published new data from 28 countries today and shown that nearly 70% of the world hepatitis burden is borne by these countries.
The National Research Foundation (NRF) and the Ministry of Education (MOE) announced today the funding support for a Research Centre of Excellence (RCE) called the Singapore Centre on Environmental Life Sciences Engineering (SCELSE) to be set up at the Nanyang Technological University (NTU).
Hematopoietic stem cells, that form mature blood cells, require a very precise amount of protein to function - and defective regulation of protein production is common in certain types of aggressive human blood cancers.
Researchers presented data today on ARQ 092, an AKT inhibitor in Phase 1 clinical development by ArQule, Inc. at the AACR Annual Meeting held in Washington, D.C., April 6-10, showing that this novel, oral agent inhibits the AKT pathway and has a manageable safety profile in an ongoing Phase 1 clinical trial.
› Verified 5 days ago
News Archive
A selection of health policy stories from Texas, Ohio, Colorado, North Carolina, Massachusetts, Alabama, Connecticut and Kansas.
July 28th is marked as world hepatitis day. The world is united in elimination of viral hepatitis by 2030. The World Health Organization (WHO) has published new data from 28 countries today and shown that nearly 70% of the world hepatitis burden is borne by these countries.
The National Research Foundation (NRF) and the Ministry of Education (MOE) announced today the funding support for a Research Centre of Excellence (RCE) called the Singapore Centre on Environmental Life Sciences Engineering (SCELSE) to be set up at the Nanyang Technological University (NTU).
Hematopoietic stem cells, that form mature blood cells, require a very precise amount of protein to function - and defective regulation of protein production is common in certain types of aggressive human blood cancers.
Researchers presented data today on ARQ 092, an AKT inhibitor in Phase 1 clinical development by ArQule, Inc. at the AACR Annual Meeting held in Washington, D.C., April 6-10, showing that this novel, oral agent inhibits the AKT pathway and has a manageable safety profile in an ongoing Phase 1 clinical trial.
› Verified 5 days ago
Cvs Pharmacy # 01855 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 66 South Main St, Sharon, Massachusetts 02067 Phone: (781) 784-6714 |